Relief Therapeutics is a Swiss, commercial-stage biopharmaceutical company, developing and commercializing novel, patent-protected products in selected specialty, rare and ultra-rare diseases.
We are currently focused on three therapeutic areas where we can best leverage our internal know-how and assets: rare dermatologic disorders, rare metabolic disorders, and rare pulmonary diseases, with particular emphasis on conditions with dermatological manifestations. We also leverage our internal research and development capabilities to identify, develop and commercialize repurposed drugs with proven safety and efficacy.
Our diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including RLF-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa, an indication for which the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation.
Founded in 2013 by three former Merck employees, Relief Therapeutics embarked on a mission to develop atexakin alfa – a human recombinant version of interleukin-6 aimed at treating peripheral neuropathy. Since its inception, the Company significantly broadened its portfolio and drug pipeline.
An overview of our product portfolio can be found on the pipeline page of our website.
Mr. Galfetti has more than thirty years of management experience in the pharmaceutical sector including in the areas of business development and licensing, operational strategic management, clinical research and pharmaceutical discovery and development. He held management positions in our organization since 1995 and currently serves as the Company’s Chief Business Officer.
Mr. Reiner has over 30 years of R&D experience. He is leading the development of Relief's pharmaceutical technologies and new products. Mr. Reiner holds a Master's degree in Pharmaceutical Chemistry and Technology from the University of Pharmacy in Milan, Italy.
Mr. Meinen serves as Chief Financial Officer and Treasurer. Prior to joining Relief in April 2020, Mr. Meinen provided financial consulting and controlling services to companies in various industries. He is a Swiss certified public accountant and former licensed audit expert.
Mr. Gallo has over 10 years legal expertise in the pharmaceutical industry, gained in both large international and start-up corporations. At Relief, he oversees legal and compliance matters, including employment law and intellectual property.
Relief is strongly supported by a highly knowledgeable Board of Directors with extensive experience in the healthcare industry and capital markets.
Raghuram (Ram) Selvaraju, Ph.D., MBA, is a Managing Director and Senior Healthcare Analyst in the Equity Research Division of H.C. Wainwright & Co., a New York-based full-service investment bank heavily focused on the healthcare sector. He has over 15 years of experience on Wall Street and previously was a pharmaceutical researcher at Serono in Switzerland. He holds Ph.D. and M.S. degrees from the University of Geneva and an M.B.A. from Cornell University.
Mr. de Svastich is a Managing Director at GEM. Mr. de Svastich has deep expertise in the areas of commercial banking, investment banking and alternative investments.
Mr. Van Beek is a Managing Director at GEM, focusing on special situation investments in both public capital markets and private opportunities. He has 25 years of experience in private equity, portfolio management, investment research and strategy.
Mr. Elzinga is an Investment Associate at GEM. He is responsible for evaluating both public and private investment opportunities, as well as managing portfolio businesses.